Pleurodesis – Internal Medicine Service Series

Authors

  • Pedro Bettencourt Medeiros Serviço de Medicina Interna do Hospital de Santo António - Centro Hospitalar do Porto, Porto, Portugal
  • Eugénia Rosendo Serviço de Oncologia Médica, Hospital de Santo António - Centro Hospitalar do Porto, Porto, Portugal
  • Célia Cruz Serviço de Medicina Interna do Hospital de Santo António - Centro Hospitalar do Porto, Porto, Portugal
  • Miguel Ricardo Serviço de Medicina Interna do Hospital de Santo António - Centro Hospitalar do Porto, Porto, Portugal
  • Fernanda Almeida Serviço de Medicina Interna do Hospital de Santo António - Centro Hospitalar do Porto, Porto, Portugal
  • João Araújo Correia Serviço de Medicina Interna do Hospital de Santo António - Centro Hospitalar do Porto, Porto, Portugal

DOI:

https://doi.org/10.24950/rspmi.943

Keywords:

Palliative Care, Pleural Effusion, Malignant, Pleurodesis

Abstract

Introduction: Recurrent pleural effusion is a frequent complication of oncologic diseases that greatly affects the patients’ quality
of life. Pleurodesis is an option to treat these effusions, in order to
alleviate symptoms and to improve the quality of life. This technique can also be used to treat benign pathologies.
Objectives and Methods: retrospective descriptive study of patients that underwent a pleurodesis between the years 2009 and
2013, in an Internal Medicine Service, considering the indication for the procedure, technique, complications, success and follow
-up, seeking to compare the results with the available literature.
Results: 27 patients underwent pleurodesis during this period of time, mostly from the male sex. The average age was 67.3 years
and the main subjacent disease was lung adenocarcinoma. Recurrent malignant pleural effusion was the main indication, and the
other pleurodesis were motivated by pneumothorax. A chest tube was placed and talc was used in most cases. The technique was
successful in 70.4% of the patients. The most frequent complications were pain and fever. 48.1% of the patients were submitted to
some kind of treatment for their disease after the pleurodesis. 30-day mortality after the pleurodesis was 14.8% and 33% of patients
were alive 6 months after the technique.
Conclusion: All the pleurodesis were performed according to the established criteria. The success rates, complications and survival
were consistent with the expected values. This success rate leads
to less hospitalizations and admissions in the Emergency Department and to the improvement of the patients’ quality of life.

Downloads

Download data is not yet available.

References

Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ. Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010. Thorax 65(Suppl 2):ii32–ii40

Suárez PM, Gilart JL. Pleurodesis in the treatment of pneumothorax and pleural effusion. Monaldi Arch Chest Dis 2013;79:81-6.

Wajda A et al. Medical talc pleurodesis: which patient with cancer benefits least. J Palliat Med 2014; 17:882-888

Steger V et al. Who gains most? A 10-year experience with 611 thoracoscopic talc pleurodesis. Ann Thorac Surg 2007;83:1940-5.

Arber A et al. Malignant pleural effusion in the palliative care setting. Int J Palliat Nurs 2013; 19: 320, 322-325

Bell D, Wright G. A retrospective review of the palliative surgical management of malignant pleural effusions. BMJ Support Palliat Care 2013(in press).

Walker-Renard P, Vaughan LM, Sahn SA. Chemical pleurodesis for malignant pleural effusions. Ann Intern Med 1994;120:56–64.

Glazer M1, Berkman N, Lafair JS, Kramer MR. Successful talc slurry pleurodesis in patients with nonmalignant pleural effusion. Chest

;117:1404-9.

Vaz MC et al. Pleurodesis: technique and indications. J Bras Pneumol 2006;32:347-356

Thomas JM, Musani AI. Malignant pleural effusions: a review. Clin Chest Med 2013;34:459-71.

Bielsa S, Hernández P, Rodriguez-Panadero F, Taberner T, Salud A, Porcel JM. Tumor type influences the effectiveness of pleurodesis in malignant effusions. Lung 2011;189:151-5

Inoue T, Ishida A, Nakamura M, Nishine H, Mineshita M, Miyazawa T. Talc pleurodesis for the management of malignant pleural effusions in Japan. Intern Med 2013;52:1173-6.

Mourad IA, Abdel Rahman AR, Aziz SA, Saber NM, Fouad FA. Pleurodesis as a palliative treatment of advanced lung cancer with malignant pleural effusion. J Egypt Natl Canc Inst 2004;16:188-94.

Xia H, Wang XJ, Zhou Q, Shi HZ, Tong ZH. Efficacy and safety of talc pleurodesis for malignant pleural effusion: a meta-analysis. PLoS One

;9:e87060.

Ozyurtkan MO, Balci AE, Cakmak M. Predictors of mortality within three months in the patients with malignant pleural effusion. Eur J Intern Med 2010;21:30-4.

Gawron G, Gabryś J, Barczyk A. Talc slurry pleurodesis via chest tube in department of pulmonology--a 24-case study. Pneumonol Alergol

Pol;81:439-47.

Huggins JT, Doelken P, Sahn SA. Intrapleural therapy. Respirology 2011;16:891-9.

Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ; BTS Pleural Disease Guideline Group. Management of a malignant pleural effusion:

British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010;65 Suppl 2:ii32-40

Lumachi F1, Mazza F, Ermani M, Chiara GB, Basso SM. Talc pleurodesis as surgical palliation of patients with malignant pleural effusion. Analysis of factors affecting survival. Anticancer Res 2012;32:5071-4.

Reddy C, Ernst A, Lamb C, Feller-Kopman D. Rapid pleurodesis for malignant pleural effusions: a pilot study. Chest. 2011;139:1419-23

Additional Files

Published

2015-09-30

How to Cite

1.
Bettencourt Medeiros P, Rosendo E, Cruz C, Ricardo M, Almeida F, Araújo Correia J. Pleurodesis – Internal Medicine Service Series. RPMI [Internet]. 2015 Sep. 30 [cited 2024 Dec. 18];22(3):142-5. Available from: https://revista.spmi.pt/index.php/rpmi/article/view/943

Issue

Section

Original Articles

Most read articles by the same author(s)

1 2 3 4 > >>